In this study, a hepatocyte-specific transgenic mouse model with inducible doxycycline-dependent CREBH overexpression enabled the demonstration of therapeutic benefits of activating CREBH in experimental NAFLD. The gene discussed is CREB3L3; the disease is metabolic dysfunction-associated steatotic liver disease.